INOTREM
9.1.2023 09:01:51 CET | Business Wire | Press release
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received funding from the Crohn’s & Colitis Foundation’s IBD Ventures under a program to accelerate research and development that aim to improve the quality of life for patients with IBD. The funding will support the development of a new therapeutic approach in IBD focusing on the TREM-1 pathway.
The funding follows a R&D collaboration between Inotrem, and the Crohn’s & Colitis Foundation announced in April 2022. The R&D collaboration seeks to pave the way of a personalized medicine approach in IBD patients based on TREM-1. Under the terms of the agreement, Inotrem has access to data and bio-samples from Foundation’s IBD Plexus®, which is the largest IBD database in the US with data from over 25,000 patients. Lasting over 18 months, the project will be a cornerstone in the design of Inotrem’s first-in-human clinical study with INO-02.
There are today 10 million people worldwide suffering from IBD, and the need for new therapeutic options remains very strong. Approximately 30% of patients are unresponsive to existing therapies and even among the initial responders, in up to 10% the drugs lose efficacy over time. For a decade, Inotrem has been elucidating the biology of TREM-1 as a regulator of the immune response in both acute as well as chronic inflammatory diseases. TREM-1 is a potential important contributor to IBD pathophysiology and targeting this pathway may offer a new treatment option for IBD patients with immune dysregulation.
“We are grateful for the support of such a well-respected organization as The Crohn’s & Colitis Foundation. This funding will help us to expand our patented technology platform centered around the TREM-1 pathway and dedicated to developing new therapies for chronic inflammatory syndromes next to our existing modalities for acute diseases,” indicates Sven Zimmermann, CEO of Inotrem.
“Beyond the financial support, this is a strong recognition of Inotrem’s scientific leadership regarding the role of the TREM-1 pathway in inflammatory processes as well as our robust therapeutic approaches targeting that biological target,” says Marc Derive, Chief Scientific Officer and Cofounder of Inotrem.
About Inotrem
Inotrem S.A. is an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sebastien Gibot and Dr Marc Derive. Inotrem is supported by leading European and North American investors. www.inotrem.com
About the Crohn’s & Colitis Foundation
The Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohn's disease and ulcerative colitis, and of improving the quality of life of the millions of Americans living with IBD. The Foundation’s work is dramatically accelerating the research process through investment in research initiatives, while also providing extensive educational and support resources for patients and their families, medical professionals, and the public. For more information, visit crohnscolitisfoundation.org, call 888-694-8872, or email info@crohnscolitisfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005241/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SPIE Announces 2027 Prism Awards Finalists for Best Photonics Products4.11.2026 21:22:00 CET | Press release
The 19th annual competition recognizes groundbreaking technologies around the globe SPIE, the international society for optics and photonics, has announced finalists in the seven categories for the 2027 Prism Awards, which recognize remarkable new photonics products on the market. Winners will be announced during the awards ceremony at SPIE Photonics West on 3 February 2027 in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104613876/en/ SPIE has announced the finalists for the 2027 SPIE Prism Awards, which recognize optics and photonics innovations. Recipients will be announced at the awards ceremony on 3 February 2027 at SPIE Photonics West. During the Prism Awards, SPIE will also announce the winner of the SPIE Catalyst Award, honoring a for-profit company with social or environmental programs that have made significant advances in workplace opportunity, community engagement, or environmental
Every Critical System Should Have a Backup: Elliptic Opens Up Fast Track Monitoring to the Crypto Industry4.11.2026 21:07:00 CET | Press release
Fast Track Monitoring, powered by Elliptic Lens, gives compliance teams screening continuity when they need it most Elliptic, the leader in on-chain risk management, is making Fast Track Monitoring available to firms with digital assets exposure as a back up screening option for firms that need business continuity, if their primary screening service is unavailable and they need a second option. Criminals are increasingly using AI to scale their attacks, so on-chain risk now moves at machine speed. Compliance teams need the broadest range of options to keep screening every wallet and transaction, and a second screening provider builds resilience into any on-chain risk management approach. Elliptic recommends every business has one in place. Organizations that rely on a single screening vendor can also still need a second option. Fast Track Monitoring gives compliance teams real-time wallet and transaction screening powered by Elliptic Lens, with a clear, explainable risk score on every
Smartsheet Adds New AI Agents, Integrations and Security Advancements at ENGAGE 20264.11.2026 19:00:00 CET | Press release
New AI advancements take over status reports and routine follow-ups, powered by 20 years of workflow intelligence seeing how work happens and where it drifts, with enterprise security and governance built-in Smartsheet, the AI-powered enterprise work management platform, today announced new platform capabilities at ENGAGE 2026, its annual customer conference. The company introduced new AI agents, agentic workflows, system integrations and security controls built to end execution drift: the costly gap between what an organization sets out to deliver and what it actually delivers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104562370/en/ Today, Smartsheet introduced new AI agents, agentic workflows, system integrations and security controls built to end execution drift. AI has helped teams move faster, but it is also widening execution drift. As AI agents join people, partners and systems in doing the work, three problem
MultiBank Exchange Holding Forms Predominantly Emirati Board as Platform Records US$500 Billion in Monthly Trading Volume4.11.2026 18:54:00 CET | Press release
MultiBank Group has announced the formation of a predominantly Emirati Board of Directors for MultiBank Exchange Holding, the first interbank trading platform in the BRICS and emerging countries, which achieved in October 2026 a turnover of over US$ 0.5 Trillion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104483253/en/ Naser Taher, Chairman of MultiBank Exchange Holding, announced the board which comprises: H.H. Sheikh Juma bin Maktoum bin Juma Al Maktoum, Board Member; H.E. Sheikh Mohammed bin Saqr bin Rashid Al Nuaimi, Board Member; H.E. Mohammed Al Hakim, Vice Chairman of the Board; H.E. Ali bin Khalid bin Zayed Al Falasi, Board Member; H.E. Rashid Sultan Al Malik, Board Member; Mr. Majid Al Ghaslan, Board Member; and Mr. David Ogg, Board Member. Naser Taher, Chairman of MultiBank Exchange Holding, announced the board which comprises: H.H. Sheikh Juma bin Maktoum bin Juma Al Maktoum, Board Member. H.E. Sheikh Moham
SES Achieves Optical Communications Milestone for Future meoSphere Network4.11.2026 18:00:00 CET | Press release
High speed data transfers send SES’s CEO to space, advancing meoSphere optical network SES, in collaboration with leading space technology partners, has successfully demonstrated a bi-directional optical communications link between ground and space through its meoSphere Pathfinder 1 mission, marking an important milestone in the development of the company's next-generation meoSphere network. The achievement validates a critical technology that will support future high-capacity, secure and flexible connectivity services. During the demonstration, SES successfully transmitted video messages from CEO Adel Al-Saleh over a bidirectional optical communications link between Cailabs' optical ground station in Rennes, France, and an SES payload flying on K2’s GRAVITAS mission on their Mega-class satellite platform. The mission utilized a Mynaric CONDOR optical terminal onboard. SES designed, developed, and operated the optical mission and developed automation software that enabled the demonstra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom